ST Pharm exports $14.6 mn worth of drug ingredients to Europe

The S.Korean company overcame sales decline due to supply cut of hepatitis C treatment ingredient to Gilead Sciences

ST Pharm exports .6 mn worth of drug ingredients to Europe
Jeong Min Nam 1
2023-01-20 11:12:44 peux@hankyung.com
Bio & Pharma

ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth 18 billion won ($14.6 million) with a large European pharmaceutical company.

With the company regaining sales of 200 billion won first in five years since 2017, good performance can be expected this year as well, depending on whether candidate drugs whose ingredients the company is supplying will be approved for sale.

ST Pharm said in a regulatory filing on Thursday that it had signed an agreement to supply ingredients for phase 3 clinical trial nucleic acid treatment with a European pharmaceutical firm by Sept. 29.

"The new drug in phase 3 trial is for the treatment of arteriosclerosis. It is a contract for process performance qualification for commercial quantity pilot production needed for a new drug application," explained a company official.

ST Pharm's main product is oligonucleotides, a raw material for ribonucleic acid (RNA)-based nucleic acid therapeutics. Oligonucleotide therapeutics have mostly been used for rare diseases. The demand for raw materials in this area is increasing rapidly as the range of applications is further enlarged to chronic diseases.

The most well-known oligonucleotide therapeutics include Novartis' hyperlipidemia treatment Inclisiran, cardiovascular disease treatment Pelacarsen, Pfizer's Vupanorsen, and Ionis' Olezarsen.

The company grew mainly by supplying ingredients for hepatitis C treatment to Gilead Sciences until 2017, but the number of patients declined rapidly due to the high cure rate of Sovaldi, the drug Gilead produced based on ST Pharm's ingredients.

ST Pharm has sought a breakthrough by increasing the oligonucleotide production capacity, such as building two plants dedicated to churning out oligonucleotides.

Write to Jeong Min Nam at peux@hankyung.com

Daewoong accelerates investment in CDMO business

Daewoong accelerates investment in CDMO business

Daewoong Bio Laboratory Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development and manufacturing (CDMO) business.In its stock exchange filing on Monday, Daewoong revealed that its subsidiary Daewoong Bio

Medipost, OmniaBio to enhance cooperation for CDMO business

Medipost, OmniaBio to enhance cooperation for CDMO business

Canada's OmniaBio executives visiting Medipost CDMO facilities South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on November 30 to discuss cooperation measures related to the CDMO (contract development

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

K-bio firms embrace gene therapy CDMO as Samsung looks the other way

South Korea's first homegrown COVID-19 vaccine, SKYCovione, produced by SK Bioscience South Korea’s major biopharmaceutical companies are rapidly embracing the cell and gene therapy business under a contract drug-making mechanism while Samsung Biologics Co. remains lukewarm toward the eme

(* comment hide *}